Biopharma

#Biopharma #CAR-T #Cell therapy

Kite releases long-term data for cell therapy  

Biopharmaceutical company Kite has announced long-term follow up results of two studies for its CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The results of both a three- and two-year follow-up of the company’s ZUMA trial were announced at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. … Read More

#News

Cell and gene therapy
#Biopharma #Cell and gene therapy #CRISPR

Selecting the best gene delivery method

Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation. No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods. The uses of… Read More

#News

#Biopharma #Covid-19 #mRNA #Vaccines

mRNA vaccines – how do we keep up with the new kid on the block? 

By Greg Kulnis  - Vice President, Customer Solutions (Infectious Disease) for Nexelis The Covid-19 pandemic has led to unprecedented collaboration and acceleration in vaccine development. In the past two years, many leading pharmaceutical and biotech companies have shifted their research and development (R&D) focus to tackle the threat of SARS-CoV-2. Read More

#Exclusive Content

Human brain
#Biopharma #Cell and gene therapy #EMA #Rare disease

Gene therapy for rare brain disease gets nod from EMA

A gene therapy targeting a rare brain disorder has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). PTC Therapeutics’ one-time gene replacement therapy Upstaza was given a positive opinion for the treatment for aromatic L-amino acid decarboxylase (AADC)… Read More

#News

#Biopharma #Covid-19 #Pandemic

NIAID to establish research centres to combat future pandemics  

The National Institute of Allergy and Infectious Diseases (NIAID) is investing $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, the organisation has announced.   The AViDD centers will conduct multidisciplinary research to develop candidate Covid-19 antivirals and others targeting specific viral… Read More

#Covid-19 #News

#Biologics / Biotechnology #Biopharma #Investment #LSX World Congress #Supply chain

Comment – pharma trends at LSX World Congress  

The LSX World Congress returned for an in-person event in May, bringing together executives from the biotech, medtech and healthtech sectors, across two days to examine the latest trends across life sciences.  DDW’s Reece Armstrong attended the event – here are the key takeaways from the show.  One of the… Read More

#Exclusive Content #Opinion

Medical researcher
#Biopharma #Cell line development #Cell lines

Balancing speed and quality in CLD for faster drug development

Listen to this article on the DDW Podcast: As Chief Technical Lead and a Head of R&D at Samsung Biologics America, Soojin Han examines the challenges, tactics, and best partnering practices in cell line development (CLD). She emphasises the need to ensure a balance between shortening commercial CLD timelines, increasing efficiencies… Read More

#Exclusive Content #Opinion

#Automation / robotics #Biologics #Biopharma #Drug development

Driving production in biologics development with automation

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. Read More

#News

#Biopharma #Cell and gene therapy #Manufacturing #Project Farma

Cell and gene therapies: Opportunities for innovation

By Dr. Deborah Phippard, Chief Scientific Officer of Precision for Medicine and Anshul Mangal, President & General Counsel, Project Farma. In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new… Read More

#Business & Investment #Exclusive Content

#Biopharma #Clinical research #Oncology

Biomunex appoints CSO to drive oncology R&D  

Biopharma company Biomunex Pharmaceuticals has appointed a new chief scientific officer (CSO) to the company and member of its scientific advisory board.   The company has appointed Dr Simon Plyte as CSO who joins Biomunex to help strengthen its R&D strategy.   Dr Plyte brings a wealth… Read More

#News

#Biopharma #Clinical trial #Covid-19 #Genetics #Vaccines

This week in drug discovery (18-22 April)  

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new… Read More

#News

#Biopharma #Synthetic biology

Evonetix granted patent for DNA synthesis tech 

Synthetic biology company Evonetix’ has been granted a patent in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips.  The EP3551331B1 patent will extend Evonetix’s IP portfolio and will help the company stratetgy’s for developing… Read More

#News

#Biopharma #Market reporting #Moderna #Pfizer #Pharma

What drove the top bio/pharma companies’ growth in 2021? 

The top 20 global innovative bio/pharma companies* reported a 24.9% growth in aggregate market capitalisation (MCAP)—from $2.8 trillion on 31 December 2020 to $3.4 trillion as of 31 December 2021, according to GlobalData.   The data and analytics company notes that a positive year-on-year MCAP growth was reported for 14 of… Read More

#News #Trending News #Trends & Analysis

#Biopharma #Biotechnology #Drug innovation #Pharmaceuticals #Report #Research

Pharmaceuticals and biotech lead UK university innovation 

University technology and innovation is driving the UK's status in pharmaceuticals and biotechnology, according to GovGrant’s University Spinouts Report 2021.  The report  According to the new report, the pharmaceuticals and biotechnology sector dominates the top ten spinout companies of the last decade, ranked by valuation. Pharma and biotech companies within the top… Read More

#News #Trends & Analysis

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Learn about immunophenotyping and advanced cell function assays

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News

#Biopharma #Cancer research #Cell therapy #Drug discovery #Flow Cytometry #Immuno-oncology #Immunology #Webinar

Deriving context from immunological data with flow cytometry – Webinar

Advances in treatments for human diseases, including cancer, rely on the ability to gain detailed information into the function, modulation, and variation of the immune system in response to stimuli or immunological challenge. Insights derived from these data have, for example, revolutionised cancer treatment by enabling the development of… Read More

#News